Target intelligence / Profile preview

BTB (POZ) domain containing 19 (BTBD19)

Target
BTBD19
Molecular classification
Other, BTB/POZ domain-containing protein, protein-protein interaction modules, transcriptional regulators
01

Overview

BTB (POZ) domain containing 19 is a member of the BTB/POZ domain protein family. The BTB domain is a protein-protein interaction motif found in various transcription factors and other intracellular proteins, often involved in transcriptional regulation and chromatin remodeling. BTBD19 has been implicated in transcriptional regulation and genome stability functions, mainly inferred from the general behavior of BTB domain proteins. Recent genomic analyses have highlighted BTBD19 as an epigenetically deregulated gene whose altered methylation status correlates with expression and prognosis in clear cell renal cell carcinoma, suggesting its utility as a prognostic biomarker but not as a direct drug target. BTBD19 is correctly named and classified. It is not a typical therapeutic target; rather, its main biomedical relevance resides in gene regulation and cancer prognosis biomarker potential, not as a receptor, enzyme, or other druggable entity.

Other names
BTB/POZ domain-containing protein 19BTBD19BTB (POZ) domain containing 19novel BTB domain containing protein
02

Mechanism of action

None known; mechanisms of action for drugs targeting this molecule are not described, as BTBD19 is not currently a therapeutic target

03

Biological functions

Protein-protein interactionsTranscriptional regulation (based on the properties of the BTB domain itself)May impact genome stability and chromatin structure indirectly
04

Disease associations

Cancer: BTBD19's methylation status has been linked to prognosis in clear cell renal cell carcinoma (ccRCC), suggesting a role as a putative biomarkerOther: No strong evidence associating BTBD19 directly with other disease classes has been published.
05

Safety considerations

None known or described
06

Interacting drugs

None known or described
07

Biomarkers

DNA methylation status of BTBD19 may be used as a biomarker for prognosis in clear cell renal cell carcinoma

Beyond the preview

Go deeper on BTB (POZ) domain containing 19 (BTBD19).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on BTB (POZ) domain containing 19 (BTBD19).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call